Publications by authors named "Dena DeMarco"
Article Synopsis
- Epcoritamab is a bispecific antibody targeting CD3 and CD20, designed to activate T cells to kill cancerous B cells and is currently in a phase I/II clinical trial to find the safest and most effective dose.
- The trial involves a unique pharmacokinetic/pharmacodynamic model to better predict how the drug interacts with the body and how it influences tumor response, rather than using traditional modeling methods which may not be sufficient.
- Results indicate that a dose of 48 mg optimally triggers T cell responses in conditions like diffuse large B-cell lymphoma and follicular lymphoma without significantly increasing the risk of cytokine release syndrome.
Article Synopsis
- A study has been conducted to evaluate the safety and optimal dosage of epcoritamab, a bispecific antibody targeting CD3 and CD20, for treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- Conducted across four countries, 73 adults participated, receiving escalating doses of the drug, with 68 patients completing the regimen without reaching maximum toxic limits.
- Results showed that the recommended phase 2 dose is 48 mg, with manageable side effects predominantly including mild fever and injection site reactions, and no severe adverse events or treatment-related deaths reported.
Background/purpose: The incidence of multiple myeloma in Asia has risen in the past 30 years. Lenalidomide, an IMiD immunomodulatory agent, has improved the overall survival in patients with relapsed/refractory multiple myeloma (RRMM) when used with dexamethasone versus dexamethasone alone. This observational registry (T-CC-MM-009; NCT01752075) assessed the safety and efficacy of lenalidomide plus dexamethasone in a large Chinese population of patients with RRMM.
View Article and Find Full Text PDFBackground: The efficacy and safety of lenalidomide plus low-dose dexamethasone (Rd) in Chinese patients with relapsed/refractory multiple myeloma (RRMM) was demonstrated in a phase 2, multicenter trial (MM-021). MM-024 was an Extended Access Program (EAP) that allowed responding patients in the MM-021 trial to continue to receive Rd, and to provide additional safety and efficacy data with longer follow-up.
Methods: Chinese patients with RRMM who completed ≥ 1 year of Rd therapy in MM-021 and who remained progression-free under Rd entered the Treatment Phase of the MM-024 EAP, continuing Rd at the same dose and schedule.
Lower starting doses of lenalidomide (LEN) are recommended for patients with renal impairment (RI). In the present study, we conducted a subgroup analysis of the MM-021 registration trial to investigate the efficacy and safety of LEN plus low-dose dexamethasone (LoDEX) in Chinese patients with advanced relapsed or refractory multiple myeloma (RRMM) based on levels of RI. Patients received LEN+LoDEX until disease progression or discontinuation.
View Article and Find Full Text PDF